Navigation Links
deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis

REYKJAVIK, Iceland, October 12, 2011 /PRNewswire/ --

deCODE genetics today announced that it has entered into a research collaboration with Pfizer Inc., the objective of which is to discover sequence variants associated with specific clinical phenotypes related to Systemic Lupus Erythematosis by utilizing deCODE's expertise in gene discovery.

deCODE's discovery capabilities combine its extensive population and genetic resources, including DNA samples and medical data, complete genealogical information, next generation sequencing technology, and deCODE's proprietary bioinformatics and statistical capabilities. Over the next 18 months, deCODE and Pfizer will work together to analyse the genomes of patients to search for sequence variants that would be useful for understanding drug targets and discovering novel drug targets, that may ultimately lead to tools for patient stratification and companion diagnostics.

"This agreement is a part of deCODE's ongoing strategy to unleash the value of human genetics," said Kari Stefansson, founder and CEO of deCODE, "our research platform allows us to understand the genetic basis of disease and modifiers of clinical phenotypes in actual patient populations; by doing so, we can rapidly move from targets to patient stratification and from there to companion diagnostics."

The research collaboration will utilize the expertise and capabilities of both deCODE and Pfizer: deCODE's comprehensive population genetics resources and analytical expertise and Pfizer's dedication to the application of genomic analysis to the discovery and development of drugs.

About deCODE

Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.

In order to most rapidly realize the value of genetics for human health, deCODE is currently partnering with life sciences companies to accelerate their target discovery, validation, and prioritization efforts, yielding improved patient stratification for clinical trials and essential companion diagnostics. In addition, through its CLIA- and CAP-certified laboratory, deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases.  deCODE also licenses its tests, intellectual property, and analytical tools to partner organizations.  deCODE's corporate information can be found at with information about our genetic testing services at and

Gisli Arnason


SOURCE deCODE genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
2. deCODE genetics, Together with Academic Collaborators and Illumina, Discovers Genetic Risk Factor for Skin, Prostate and Brain Cancers
3. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
4. The New deCODE Map of the Human Genome
5. deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma
6. ARUP Laboratories Ink Partnership to Offer deCODE ProstateCancer(TM) Test
7. deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases
8. deCODE Finds Genetic Factors Impacting Key Clinical Measurements of Heart Activity and Disease Risk
9. deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal
10. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
11. Amaizing: Corn genome decoded
Post Your Comments:
(Date:11/23/2015)... ... 2015 , ... Noblis, Inc., a leading provider of science, technology, and strategy ... Intelligence Agency (NGA), has joined the Noblis NSP team as President of the organization. ... community and the private sector,” said L. Roger Mason, Jr., Ph.D. , Senior ...
(Date:11/23/2015)... and PISCATAWAY, New Jersey , ... Crystallographic Data Centre (CCDC) announces the launch ... Database (CSD) and the CSD-System, now complemented by ... CSD-Discovery to support the discovery of new molecules, ... CSD-Enterprise, the complete set of the CCDC,s applications ...
(Date:11/23/2015)... -- CryoLife, Inc. (NYSE: CRY ), a leading medical device ... announced today that it will participate in the upcoming 27 ... 2, 2015 at The New York Palace Hotel in ... , President and Chief Executive Officer. --> ... --> A live webcast of the Company,s presentation is ...
(Date:11/23/2015)... , Nov. 23, 2015  Oxis Biotech, Inc. ... Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced ... Masonic Cancer Center received notification from the U.S. ... proceed with their planned combination Phase 1/Phase 2 ... rights to develop and commercialize OXS-1550, a novel ...
Breaking Biology Technology:
(Date:11/19/2015)... MOUNTAIN VIEW, Calif. , Nov. 19, 2015 /PRNewswire/ ... authentication market, Frost & Sullivan recognizes BIO-key with the ... Strategy Leadership. Each year, Frost & Sullivan presents this ... comprehensive product line catering to the needs of the ... which the product line meets and expands on customer ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
Breaking Biology News(10 mins):